Original articleBreast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer
Introduction
The significant decrease in breast cancer mortality, which amounts to nearly 30% since 1990, is a major medical success and is due in large part to the earlier detection of breast cancer through mammographic screening. Nevertheless, major efforts continue to build on this success by developing additional methods to screen for early breast cancer. Consequently, recommendations for breast cancer screening with imaging technologies have become increasingly complex. Several organizations, most notably the American Cancer Society (ACS) [1], have guidelines that are largely evidence-based, for how screening mammography should be used. In addition, the ACS has issued guidelines, also based predominately on existing evidence, for the use of magnetic resonance imaging of the breast to screen for breast cancer [2]. However, there are gaps in these guidelines, undoubtedly due to a lack of data concerning many aspects of the optimal utilization of available screening tests. To address some of these gaps, the Society of Breast Imaging (SBI) and the ACR, whose members are directly responsible for performing these screening tests, have performed and analyzed many of the trials establishing appropriate screening algorithms, and have the most expertise in these technologies, are issuing these guidelines and recommendations for breast cancer screening. Whenever possible, these are based on peer-reviewed published scientific data. Where data are lacking, the recommendations reflect expert consensus opinions by the fellows of the SBI and the members of the Breast Imaging Commission of the ACR. These guidelines and recommendations are intended to suggest appropriate utilization of imaging modalities for screening. They are not intended to replace sound clinical judgment and are not to be construed as representing the standard of care. It should be remembered that mammography is the only imaging modality that has been proven to decrease mortality from breast cancer.
The SBI and the ACR also wish to remind women and their physicians that in those instances in which there is a concern that risk for developing breast cancer is considerably elevated above that of the general population, consultation with appropriate experts in breast cancer genetics or high-risk management is desirable.
Section snippets
1. Mammography
- •
Women at average risk for breast cancer
- ∘
Annual screening from age 40
- ∘
- •
Women at increased risk for breast cancer
- ∘
Women with certain BRCA1 or BRCA2 mutations or who are untested but have first-degree relatives (mothers, sisters, or daughters) who are proved to have BRCA mutations
- ■
Yearly starting by age 30 (but not before age 25)
- ■
- ∘
Women with ≥20% lifetime risk for breast cancer on the basis of family history (both maternal and paternal)
- ■
Yearly starting by age 30 (but not before age 25), or 10 years
- ■
- ∘
Screening Annually Beginning at Age 40
Evidence to support the recommendation for regular periodic screening mammography comes from the results of several randomized controlled trials (RCTs) conducted in Europe and North America [3, 4, 5, 6, 7, 8, 9, 10] that included a total of nearly 500,000 women. The trials varied in age of included women and in screening frequency, but all but 1 demonstrated statistically significant decreases in breast cancer mortality among the populations invited to screening. Overall, on the basis of a
Acknowledgments
We gratefully acknowledge the assistance received from Dr Robert Smith of the ACS and from the fellows of the SBI in formulating these recommendations. We also acknowledge the help of Pamela Wilcox of the ACR and Michele Wittling of the SBI, without whose assistance this document would not have been possible.
References (82)
- et al.
Screening and breast cancer mortality, age specific effects in Nijmegen project, 1975-82
Lancet
(1985) - et al.
Breast cancer screening with mammography: overview of Swedish randomized trials
Lancet
(1993) - et al.
Radiological findings of screen-detected cancers in a multi-centre randomized, controlled trial of mammographic screening in women from age 40 to 48 years
Clin Radiol
(2006) - et al.
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial
Lancet
(2006) Breast imaging and the conservative treatment of breast cancer
Radiol Clin N Am
(2002)- et al.
Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk
Int J Radiat Oncol Biol Phys
(2001) - et al.
Is screening mammography effective in elderly women?
Am J Med
(2000) - et al.
Clinically and mammographically occult breast lesions: detection and classification with high resolution sonography
Semin Ultrasound CT MR
(2000) Ultrasound for breast cancer screening and staging
Radiol Clin N Am
(2002)- et al.
American Cancer Society guidelines for breast cancer screening: update 2003
CA Cancer J Clin
(2003)
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography
CA Cancer J Clin
Periodic screening for breast cancer: the Health Insurance Plan Project and its sequelae, 1963-1986
Edinburgh trial of screening for breast cancer: mortality at seven years
Lancet
Canadian national breast screening study: 1: breast cancer detection and death rates among women aged 40 to 49 years
CMAJ
Canadian national breast screening study: 2: breast cancer detection and death rates among women aged 50 to 59 years
CMAJ
A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer
J Epidemiol Commun Health
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review
Lancet
Efficacy of screening mammographyA metaanalysis
JAMA
Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality
Cancer
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties
Cancer
Breast cancer screening among women in their forties: an overview of the issues
J Natl Cancer Inst Monogr
Screening: assessment of current studies
Cancer
Screening mammography in women younger than 50 years of age
Ann Inter Med
Informed decision making: age of 50 is arbitrary and has no demonstrated influence on breast cancer screening in women
AJR Am J Roentgenol
Biasing the interpretation of mammography screening data by age grouping: nothing changes abruptly at age 50
Breast J
Positive predictive value of screening mammography by age and family history of breast cancer
JAMA
Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials
J Natl Cancer Inst
Benefit of screening mammography in women ages 40-49: a new meta-analysis of randomized controlled trials
Monogr Natl Cancer Inst
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Ann Intern Med
Screening for breast cancer: An update for the U.S. Preventive Services Task Force
Ann Inter Med
Effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms
Ann Intern Med
Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians
Ann Intern Med
Malignant tumors of the breast
A different perspective on breast cancer risk factors: some implications of nonattributable risk
CA Cancer J Clin
Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer
AJR Am J Roentgenol
Follow up and final results of the Oslo I study comparing screen-film mammography and full-field digital mammography with soft copy reading
Acta Radiol
Diagnostic performance of digital versus film mammography for breast cancer screening
N Engl J Med
Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population based screening program: follow-up and final results of Oslo II study
Radiology
Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST
Radiology
Second malignant neoplasms among long-term survivors of ovarian cancer
Cancer Res
Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathological analysis of 45 events in 37 patients
J Clin Oncol
Cited by (659)
AAPFC-BUSnet: Hierarchical encoder–decoder based CNN with attention aggregation pyramid feature clustering for breast ultrasound image lesion segmentation
2024, Biomedical Signal Processing and ControlLAMIS-DMDB: A new full field digital mammography database for breast cancer AI-CAD researches
2024, Biomedical Signal Processing and ControlDeep learning for computer-aided abnormalities classification in digital mammogram: A data-centric perspective
2024, Current Problems in Diagnostic RadiologyBest practice & research clinical haematology: Screening for breast cancer in hodgkin lymphoma survivors
2023, Best Practice and Research: Clinical Haematology
Disclosures: P. Evans, Hologic, Inc., consultant, Scientific Advisory Board. B. Monsees, Hologic, Inc., member, Advisory Board. L. Bassett, Hologic, Inc., consultant, Research Advisory Committee. W. Berg, Naviscan, Inc., consultant; Medipattern, Inc., consultant. E. Hendrick, GE Healthcare, consultant, member, Advisory Board; Koning, Corp., member, Advisory Board; Bracco Imaging, SpA, member, Advisory Board. E. Mendelson, Hologic, Inc., member, Medical Advisory Board; Siemens Medical Systems, investigator; Supersonic Imaging, investigator and speaker; Toshiba Ultrasound, speaker. C. D'Orsi, Hologic, Inc., consultant. L.W. Burhenne, Hologic, Inc., member, Advisory Committee.